ChiCTR2400079922 版本V1.0 版本创建时间2024/01/16 14:26:40 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400079922 

最近更新日期:

Date of Last Refreshed on:

2024-01-16 14:26:15 

注册时间:

Date of Registration:

2024-01-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

右美托咪定对高原地区肝部分切除手术后肝功能亚急性损伤的影响研究

Public title:

The effect of dexmedetomidine on subacute liver function injury after partial hepatectomy in high-altitude areas

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右美托咪定对高原地区肝部分切除手术后肝功能亚急性损伤的影响研究

Scientific title:

The effect of dexmedetomidine on subacute liver function injury after partial hepatectomy in high-altitude areas

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王虹霞 

研究负责人:

王虹霞 

Applicant:

Wang Hongxia 

Study leader:

Wang Hongxia 

申请注册联系人电话:

Applicant telephone:

+86 139 9722 2705

研究负责人电话:

Study leader's
telephone:

+86 139 9722 2705

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

448290102@qq.com

研究负责人电子邮件:

Study leader's E-mail:

448290102@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

青海省西宁市城西区文景街9号新华联家园

研究负责人通讯地址:

青海省西宁市城西区文景街9号新华联家园

Applicant address:

Xinhualian Jiayuan, No. 9 Wenjing Street, Chengxi District, Xining City, Qinghai Province

Study leader's address:

Xinhualian Jiayuan, No. 9 Wenjing Street, Chengxi District, Xining City, Qinghai Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

青海省人民医院

Applicant's institution:

Qinghai Provincial People's Hospital

研究负责人所在单位:

青海省人民医院

Affiliation of the Leader:

Qinghai Provincial People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科研伦审(2023)-278

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

青海省人民医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of Qinghai Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-12-27 00:00:00

伦理委员会联系人:

韩培

Contact Name of the ethic committee:

Hanpei

伦理委员会联系地址:

青海省西宁市城东区共和路2号

Contact Address of the ethic committee:

No. 2 Gonghe Road, Chengdong District, Xining City, Qinghai Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 971 806 6221

伦理委员会联系人邮箱:

Contact email of the ethic committee:

qhsrmyykllwyh@163.com

研究实施负责(组长)单位:

青海省人民医院

Primary sponsor:

Qinghai Provincial People's Hospital

研究实施负责(组长)单位地址:

青海省西宁市城东区共和路2号

Primary sponsor's address:

No. 2 Gonghe Road, Chengdong District, Xining City, Qinghai Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

青海省

市(区县):

西宁市

Country:

China

Province:

Qinghai Province

City:

Xining City

单位(医院):

青海省人民医院

具体地址:

青海省西宁市城东区共和路2号

Institution
hospital:

Qinghai Provincial People's Hospital

Address:

No. 2 Gonghe Road, Chengdong District, Xining City, Qinghai Province

经费或物资来源:

自筹

Source(s) of funding:

raise independently

研究疾病:

高原地区肝部分切除手术后肝功能亚急性损伤  

Target disease:

subacute liver function injury after partial hepatectomy in high-altitude areas

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

IV期临床试验 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究右美托咪定对高原地区行肝部分切除手术患者血流动力学的影响;探究右美托咪定对高原地区行肝切除手术患者术后炎症反应、远端器官功能的影响;探究右美托咪定对高原地区行肝切除手术患者术后亚急性肝功能损伤的影响。  

Objectives of Study:

Exploring the effect of dexmedetomidine on hemodynamics in patients undergoing partial hepatectomy in high-altitude areas; Exploring the effects of dexmedetomidine on postoperative inflammatory response and distal organ function in patients undergoing liver resection surgery in high-altitude areas; Exploring the effect of dexmedetomidine on postoperative subacute liver function damage in patients undergoing liver resection surgery in high-altitude areas.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

入选标准(研究前,受试者必须满足以下所有要求,方可入组) 1 年龄18-70岁,性别不限; 2 海拔2500米以上地区常住人口; 3 在本院行肝切除手术,且术中使用Pringle手法进行全肝门阻断; 4 美国麻醉师协会(ASA)分级Ⅰ~III级; 5 受试者知情自愿参加,并签署知情同意书。

Inclusion criteria

Inclusion criteria (Prior to the study, participants must meet all of the following requirements in order to be enrolled) 1 Age range from 18 to 70 years old, regardless of gender; 2 Permanent population in areas above 2500 meters above sea level; 3 Perform liver resection surgery in our hospital, and use Pringle technique for total hepatic portal block during the operation; 4 American Society of Anesthesiologists (ASA) classification I to III levels; 5 Participants are informed and voluntarily participate, and sign an informed consent form.

排除标准:

排除标准(研究前,受试者若满足以下任一项要求,不可入组): 1 合并严重心、肺、脑、肾等重要脏器疾病的患者; 2 肺功能障碍(PaO2<60mmHg)或合并慢性阻塞性肺疾病的患者; 3 合并高血压、糖尿病等慢性疾病的患者; 4 合并神经精神障碍的患者; 5 既往3月内发生过严重心肌梗死的患者; 6 肝肿瘤破裂或出血; 7 孕妇或哺乳期妇女。

Exclusion criteria:

Exclusion criteria (prior to the study, subjects are not eligible for enrollment if they meet any of the following requirements): 1. Patients with severe heart, lung, brain, kidney and other important organ diseases; Patients with pulmonary dysfunction (PaO2<60mmHg) or concomitant chronic obstructive pulmonary disease; Patients with chronic diseases such as hypertension and diabetes; Patients with concomitant neurological and psychiatric disorders; Patients who have experienced severe myocardial infarction within the past three months; Rupture or bleeding of liver tumors; Pregnant or lactating women.

研究实施时间:

Study execute time:

From 2024-01-20 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-01-20 00:00:00 To 2024-12-20 00:00:00

干预措施:

Interventions:

组别:

右美托嘧啶

样本量:

36

Group:

dexmedetomidine

Sample size:

干预措施:

术中采用负荷剂量加持续输注的方式静脉给药右美托嘧啶

干预措施代码:

Intervention:

Intraoperative intravenous administration of dexmedetomidine using a loading dose combined with continuous infusion

Intervention code:

组别:

对照组

样本量:

36

Group:

Control group

Sample size:

干预措施:

以相同负荷剂量和持续输注速率静脉给药0.9%氯化钠

干预措施代码:

Intervention:

Intravenous administration of 0.9% sodium chloride at the same loading dose and continuous infusion rate

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

青海省 

市(区县):

西宁市 

Country:

China

Province:

Qinghai Province

City:

Xining City

单位(医院):

青海省人民医院 

单位级别:

三甲 

Institution
hospital:

Qinghai Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肝功能

指标类型:

主要指标

Outcome:

liver function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

次要指标

Outcome:

Renal function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

blood routine examination

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

凝血功能

指标类型:

次要指标

Outcome:

Blood coagulation function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

炎症因子

指标类型:

次要指标

Outcome:

inflammatory factor

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血流动力学指标

指标类型:

次要指标

Outcome:

Hemodynamic indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

静脉血

组织:

Sample Name:

venous blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机化由计算机生成,按顺序编号通过不透明的密封信封来隐藏分配。即分别列出流水号为001~072所对应的治疗分配(随机编码表),且流水号与受试者编号对应,随机编码表由指定人员保管。在手术当天早上,负责用相同的注射器准备右美托嘧啶或生理盐水空白对照的护士打开信封,进行治疗分配。然后麻醉师在不知情的情况下给药。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization is generated by computers, with sequential numbering hidden through opaque sealed envelopes for allocation. Namely, list the treatment allocation (random code table) corresponding to serial numbers 001~072 separately, and the serial number corresponds to the subject number. The random code table is kept by designated personnel. On the morning of the surgery day, the nurse responsible for preparing a blank control of dexmedetomidine or physiological saline using the same syringe opened the envelope and assigned treatment. Then the anesthesiologist administered the medication without their knowledge.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

在最终的统计分析完成之前,患者、外科医生、调查人员和统计分析人员都对分组分配不知情。

Blinding:

Before the final statistical analysis is completed, patients, surgeons, investigators, and statistical analysts are all unaware of the grouping allocation.

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

not shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集:病例记录表 电子采集和管理系统:白塔数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection: Case record form Electronic Collection and Management System: White Tower Data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-01-16 14:26:15